Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Merck Sharp & Dohme (Australia) Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (115)
ARTG (99)
Prescription medicine registration (52)
Australian Public Assessment Report (AusPAR) (31)
Designation or determination (31)
Prescription medicine evaluation (9)
Prescription medicine decision summary (2)

Date

2024 (25)
2023 (33)
2022 (29)
2021 (31)
2020 (37)
2019 (52)
2018 (23)
2017 (3)
2016 (10)
2015 (6)
2014 (12)
2013 (16)
2012 (6)
2011 (4)
2009 (10)
2008 (6)
2007 (6)
2006 (10)
2005 (1)
2003 (1)
2002 (7)
2000 (1)
1998 (1)
1997 (5)
1996 (1)
1993 (1)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

339 result(s) found, displaying 71 to 80

ZINPLAVA bezlotoxumab (rch) 1000 mg/40 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
Merck Sharp & Dohme Australia Pty Ltd - Medicine administration kit, oral Cancelled under Section 41GL(d) of the Act

22 June 2022

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
Merck Sharp & Dohme Australia Pty Ltd - Medicine administration kit, oral Cancelled under Section 41GL(d) of the Act

22 June 2022

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
DIFICID fidaxomicin 200 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

22 June 2022

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
EMEND aprepitant 80mg & 125mg tri-pack capsule blister pack Cancelled under Section 30(1)(c) of the Act

22 June 2022

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
EMEND aprepitant 125mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

22 June 2022

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
KEYTRUDA pembrolizumab (rch) 50 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

16 June 2022

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)

11 May 2022

Prescription medicine registration

Active ingredients: pembrolizumab.
KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)

27 April 2022

Prescription medicine registration

Active ingredients: pembrolizumab.
Notice for belzutifan (Merck Sharp & Dohme (Australia) Pty Ltd)

2 February 2022

Designation or determination

Provisional determination

Pages

First page
Previous page
…
Page 4
Page 5
Page 6
Page 7
Current page 8
Page 9
Page 10
Page 11
Page 12
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.